Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the stocks highlighted in Jim Cramer’s latest Mad Money recap as he provided top stock insights. Answering a caller’s query about the stock, Cramer said:

Too risky for me. I just think that at this stage, with this market, that one you could lose too much money. I’m very sorry.

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for women’s cancers. The company reported its Q4 2025 and full-year earnings on March 16. It posted Q4 GAAP EPS of -$0.50, exceeding estimates by $0.01. Net loss for FY25 was $162.5 million compared to $129.5 million in the prior year.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.